Pricing Log in Create free account

Latigo Biotherapeutics Inc (LTGO) vs Rigel Pharmaceuticals, Inc. (RIGL)

Latigo Biotherapeutics Inc and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Latigo Biotherapeutics Inc and Rigel Pharmaceuticals, Inc. are of similar size ($862.6M and $853.9M). Across the 3 metrics below, Rigel Pharmaceuticals, Inc. leads on 3 and Latigo Biotherapeutics Inc on 0.

Valuation

Metric LTGO RIGL Biotechnology median
P/E — 2.35 10.60
P/S n/m 2.57 9.40
P/B n/m 1.66 2.13
Price to free cash flow n/m 37.96 25.18
EV/EBITDA n/m 8.30 0.66
EV/Sales n/m 2.28 9.02
Earnings yield — 42.49% (32.88%)
Free cash flow yield 0.00% 2.63% (23.13%)

Profitability

Metric LTGO RIGL Biotechnology median
Gross margin — 89.64% 68.51%
Operating margin — 26.28% 0.00%
Net margin — 106.59% 0.00%
Free cash flow margin — 31.20% 0.00%
Return on equity — 109.18% (51.96%)
Return on assets — 80.16% (46.06%)
Return on invested capital 0.00% 13.69% 0.00%

Growth

Metric LTGO RIGL Biotechnology median
Revenue growth (TTM) — 2.18% 6.76%
EPS growth (last fiscal year) — 1,867.68% 29.88%
Revenue growth, 5-year CAGR — 22.06% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LTGO RIGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.15 2.39 4.97
Net debt to EBITDA — (1.05) 1.01

Dividend

Metric LTGO RIGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LTGO RIGL Biotechnology median
Market cap 862.55m 853.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack